Preliminary evidence for the phosphodiesterase type-4 inhibitor, roflumilast, in ameliorating cognitive flexibility deficits in patients with schizophrenia

BACKGROUND: Cognitive flexibility deficits are present in patients with schizophrenia and are strong predictors of functional outcome but, as yet, have no pharmacological treatments. AIMS: The purpose of this study was to investigate whether the phosphodiesterase type-4 inhibitor, roflumilast, can i...

Descripción completa

Detalles Bibliográficos
Autores principales: Livingston, Nicholas R, Hawkins, Peter CT, Gilleen, James, Ye, Rong, Valdearenas, Lorena, Shergill, Sukhi S, Mehta, Mitul A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435828/
https://www.ncbi.nlm.nih.gov/pubmed/33908296
http://dx.doi.org/10.1177/02698811211000778

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435828/
https://www.ncbi.nlm.nih.gov/pubmed/33908296
http://dx.doi.org/10.1177/02698811211000778

Ejemplares similares